An Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes
NCT ID: NCT02298556
Last Updated: 2018-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
270 participants
OBSERVATIONAL
2014-10-31
2016-03-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes
NCT00144144
Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients
NCT03038451
I PREVENT - Irbesartan In Hypertensive Diabetic Patients
NCT00362258
Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF
NCT01435161
Effectiveness and Safety of Combination of Nebivolol and Zofenopril in Hypertensive patIents Versus Each Monotherapy
NCT05257148
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hypertensive patients
Hypertensive patients with elevated heart rate and type 2 diabetes mellitus
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥ 18 years old
* Has been already diagnosed with hypertension
* Has been already diagnosed with type 2 diabetes mellitus
* Started using angiotensin-converting enzyme inhibitor and non-dihydropyridine calcium channel blocker single pill combination within a maximum of 1 week before enrolment
* Heart rate ≥70 beat per minute
Exclusion Criteria
* Current need to use any other antihypertensive drug(s) in addition to angiotensin-converting enzyme inhibitor and non-dihydropyridine calcium channel blocker single pill combination
* Having any contraindication for angiotensin-converting enzyme inhibitor or non-dihydropyridine calcium channel blocker;
* Has been treated by any anti-hypertensive treatment(s) before angiotensin-converting enzyme inhibitor and non-dihydropyridine calcium channel blocker single pill combination
* Is currently participating in another clinical or non-clinical study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MonitorCRO
INDUSTRY
Abbott
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Enver Atalar, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
Hacettepe University Faculty of Medicine Hospital Cardiology Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research facility ID ORG-001108
Adana, , Turkey (Türkiye)
Research facility ID ORG-001030
Ankara, , Turkey (Türkiye)
Yıldırım Beyazıt University Yenimahalle Training and Research Hospital
Ankara, , Turkey (Türkiye)
Research facility ID ORG-001111
Antalya, , Turkey (Türkiye)
Research facility ID ORG-001120
Aydin, , Turkey (Türkiye)
Research facility ID ORG-001119
Aydin, , Turkey (Türkiye)
Research facility ID ORG-001116
Balıkesir, , Turkey (Türkiye)
Research facility ID ORG-001112
Burdur, , Turkey (Türkiye)
Research facility ID ORG-001123
Çorum, , Turkey (Türkiye)
Erzurum Regional Training and Research Hospital
Erzurum, , Turkey (Türkiye)
Atatürk University Aziziye Research Hospital
Erzurum, , Turkey (Türkiye)
Research facility ID ORG-001118
Istanbul, , Turkey (Türkiye)
Bakırköy Dr. Sadi Konuk Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Research facility ID ORG-001117
Istanbul, , Turkey (Türkiye)
Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Research facility ID ORG-001125
Istanbul, , Turkey (Türkiye)
Research facility ID ORG-001113
Karabük, , Turkey (Türkiye)
Research facility ID ORG-001110
Konya, , Turkey (Türkiye)
Research facility ID ORG-001115
Kırıkkale, , Turkey (Türkiye)
Research facility ID ORG-001122
Trabzon, , Turkey (Türkiye)
Uskudar PublicHospital
Üsküdar, , Turkey (Türkiye)
Yalova Public Hospital
Yalova, , Turkey (Türkiye)
Research facility ID ORG-001124
Zonguldak, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Atalar E, Eskin F, Tugtekin HB, Karabulut A, Kanyilmaz S, Kirbiyik H, Ozyildiz AG. A Prospective Noninterventional, Observational Study to Describe the Effectiveness and Safety of Trandolapril and Verapamil Single-Pill Combination in the Management of Patients with Hypertension and Type 2 Diabetes Mellitus: A Harvest TR Study. Biomed Res Int. 2020 Sep 5;2020:2123601. doi: 10.1155/2020/2123601. eCollection 2020.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GSS-13-0019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.